OnKure Therapeutics (NASDAQ:OKUR) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of OnKure Therapeutics (NASDAQ:OKUR) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $40.00 price objective on the stock.

A number of other analysts also recently issued reports on OKUR. Lifesci Capital raised OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Oppenheimer began coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 price objective on the stock.

OnKure Therapeutics Stock Performance

Shares of OKUR traded up $0.39 during trading hours on Friday, hitting $17.58. 29,108 shares of the stock were exchanged, compared to its average volume of 30,611. The stock has a market capitalization of $58.72 million, a price-to-earnings ratio of -1.05 and a beta of 0.21. OnKure Therapeutics has a 12-month low of $9.80 and a 12-month high of $77.60.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.13). On average, analysts predict that OnKure Therapeutics will post -3.87 earnings per share for the current year.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.